A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 on ClinicalTrials.gov · last registry update 2026-09-28
Closed to new participants; the 180 already enrolled are still being followed. Due to report 25 August 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 2 times since then.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 180
- Started
- 2026-03-05
- Primary completion
- 2027-08-25 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-28 | Status changed | RECRUITING → ACTIVE_NOT_RECRUITING |
| 2026-09-28 | Reporting date moved | 2027-09-29 → 2027-08-25 1 months earlier |
Primary outcome
Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52
Conditions studied
Overweight or Obesity and Elevated Liver Fat
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.